Healthcare / BiotechnologyNasdaqCM
$10.82
-0.74 (-6.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-19.6M · quality 84.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$372M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-39.0%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-37.9M · FCF $-23.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | — | — | — | $75000.00 | $73000.00 | $59000.00 | $102000.00 | $12.2M |
| Net Income | $-37.9M | $-37.9M | $-21.8M | $-19.6M | $-18.2M | $-13.9M | $-8.3M | $2.6M |
| EBITDA | $-41.4M | $-41.4M | $-22.1M | $-18.7M | $-17.8M | $-13.4M | $-8.1M | $2.7M |
| EPS | -1.05 | -1.05 | -1.22 | -14.12 | -37.91 | -54.91 | — | — |
| Gross Margin | — | — | — | 100.0% | 87.7% | — | — | — |
| Operating Margin | — | — | — | -25441.3% | -24457.5% | -23044.1% | -8118.6% | 21.2% |
| Net Margin | — | — | — | -26082.7% | -24942.5% | -23528.8% | -8111.8% | 21.4% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 2.77 | 0.28 | — | — | — |
| Current Ratio | 56.82 | 56.82 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-23.6M | $-23.6M | $-19.6M | $-18.0M | $-15.9M | $-13.1M | $-7.6M | $4.4M |
| Returns | ||||||||
| ROE | -39.0% | -39.0% | -46.0% | -9684.2% | -631.8% | -69.4% | -80.8% | 15.7% |
| Valuation | ||||||||
| P/B | 4.03 | 4.03 | 3.61 | 28.69 | 2.62 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | — | — | — | 2.7% | — | -42.2% | -99.2% | — |
| EPS Growth | 13.9% | 13.9% | 91.4% | 62.8% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.22 → -1.05
Residual
-29.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.